Ovarian Cancer

HCG11[LncRNA]

miR-144-3p[miRNA]

PBX3[mRNA]

SKOV3 cells

Homo sapiens (human)

Eur Rev Med Pharmacol Sci. 2020 Nov;24(21):11032-11040. doi: 10.26355/eurrev_202011_23588.

Knockdown of lncRNA HCG11 suppresses cell progression in ovarian cancer by modulating miR-144-3p/PBX3.

Dual-luciferase reporter assay;MTT assay;qPCR;RT-qPCR;Western blot;Luciferase reporter assay;MTT assay;

OBJECTIVE: LncRNA HCG11 has been confirmed to act as a crucial role in several human cancers. Nevertheless, to our knowledge, the function of HCG11 on the progression of ovarian cancer (OC) has not been studied. This article is designed to explore the mechanism and role of HCG11 in the tumorigenesis and development of OC. PATIENTS AND METHODS: RT-qPCR analysis was applied to detect the expression of HCG11, miR-144-3p and PBX3 in OC tissues and cell lines. MTT assay and transwell assay were opted to measure the cell viability of OC cells. The protein expression level of PBX3 was measured by Western blot assay. Dual-Luciferase reporter assay was carried out to assess the correlation between HCG11, miR-144-3p and PBX3. RESULTS: The upregulated of HCG11 was observed in OC tissues and OC cell lines. Moreover, miR-144-3p was down expressed in OC tissues and cell lines. Functionally, the knockdown of HCG11 prevented cell viability of SKOV3 cells, while miR-144-3p inhibitor abrogated the suppressor on cell progression. Furthermore, PBX3 was verified to be a target gene of miR-144-3p. In addition, PBX3 knockdown prevented the cell progression of SKOV3 cells. CONCLUSIONS: These data displayed that the knockdown of HCG11 prevented cell progression in OC by sponging miR-144-3p and downregulating PBX3. All results revealed that HCG11 can be a potential therapeutic target for OC therapy.